v3.23.3
Consolidated Balance Sheets - USD ($)
Aug. 31, 2023
Nov. 30, 2022
Current Assets    
Cash and cash equivalents $ 583,996 $ 1,703,958
Marketable securities 623,489 17,620
Accounts receivable (net of allowance for doubtful accounts of $3,757,884 and $3,528,119, respectively) 6,437,644 6,043,941
Prepaid expenses 719,007 566,557
Inventory, current portion 1,062,859 851,230
Swap contract 58,757 0
Other current assets 450,617 426,879
Total current assets 9,936,369 9,610,185
Property and Equipment-net 18,836,456 13,603,115
Other Assets    
Duke license agreement 12,970,447 13,691,028
Intangible assets, net 1,391,026 1,463,312
Inventory, net of current portion 8,836,287 9,275,344
Goodwill 1,941,411 1,941,411
Deferred tax assets 13,742,399 13,742,399
Operating lease right-of-use asset 1,107,171 606,034
Deposits and other assets, net 726,800 647,226
Total other assets 41,023,541 41,674,754
Total assets 69,796,366 64,888,054
Current Liabilities    
Accounts payable 2,785,459 1,605,301
Accrued expenses 1,774,456 3,585,810
Note payable 162,659 150,527
Line of credit 2,722,728 2,272,728
Current portion of operating lease liability 221,062 297,691
Current portion of Duke license agreement liability 1,200,000 1,983,036
Deferred revenue 9,696,530 9,586,327
Total current liabilities 18,562,894 19,481,420
Other Liabilities    
Deferred revenue, net of current portion 39,966,150 36,000,059
Contingent consideration 1,030,050 1,162,704
Note payable, net of current portion and debt issuance costs 8,468,312 8,579,875
Operating lease long-term liability 910,123 313,298
Long-term liability - revenue sharing agreements 875,000 875,000
Total other liabilities 51,249,635 46,930,936
Total liabilities 69,812,529 66,412,356
Commitments and contingencies (Note 9) 0 0
Stockholders' Deficit    
Preferred stock ($.01 par value, 500,000 authorized and none issued and outstanding) 0 0
Common stock ($.01 par value, 20,000,000 authorized; 14,849,246 issued and 8,286,785 outstanding as of August 31, 2023 and 14,848,001 issued and 8,500,511 outstanding as of November 30, 2022) 148,492 148,480
Additional paid-in capital 43,236,194 42,597,380
Treasury stock, at cost (23,431,685) (22,632,649)
Accumulated deficit (19,969,164) (21,637,513)
Total stockholders' deficit (16,163) (1,524,302)
Total liabilities and stockholders' deficit 69,796,366 64,888,054
Series A Junior Participating Preferred Stock [Member]    
Stockholders' Deficit    
Preferred stock ($.01 par value, 500,000 authorized and none issued and outstanding) 0 0
Tianhe Stem Cell Biotechnologies Inc [Member]    
Other Assets    
Investment $ 308,000 $ 308,000

Source